Bellevue Group AG Makes New $871,000 Investment in Sanofi (NASDAQ:SNY)

Bellevue Group AG acquired a new stake in Sanofi (NASDAQ:SNY) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,109 shares of the company’s stock, valued at approximately $871,000.

A number of other hedge funds also recently modified their holdings of SNY. Tidal Investments LLC acquired a new position in Sanofi in the 1st quarter valued at about $228,000. Cetera Investment Advisers grew its position in shares of Sanofi by 245.4% in the first quarter. Cetera Investment Advisers now owns 178,349 shares of the company’s stock valued at $8,668,000 after purchasing an additional 126,712 shares during the last quarter. Cetera Advisors LLC increased its stake in shares of Sanofi by 301.6% during the first quarter. Cetera Advisors LLC now owns 60,359 shares of the company’s stock worth $2,933,000 after purchasing an additional 45,330 shares during the period. GAMMA Investing LLC lifted its holdings in Sanofi by 44.5% during the 2nd quarter. GAMMA Investing LLC now owns 3,063 shares of the company’s stock worth $149,000 after purchasing an additional 944 shares during the last quarter. Finally, Mather Group LLC. grew its holdings in Sanofi by 451.8% in the 2nd quarter. Mather Group LLC. now owns 1,948 shares of the company’s stock valued at $95,000 after buying an additional 1,595 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Ratings Changes

SNY has been the subject of a number of research reports. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

NASDAQ:SNY opened at $48.49 on Monday. The company has a market cap of $123.06 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.23 and a beta of 0.61. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The stock has a fifty day moving average price of $52.80 and a 200-day moving average price of $52.15.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the prior year, the business posted $2.55 earnings per share. Sanofi’s revenue was up 12.3% compared to the same quarter last year. As a group, equities analysts anticipate that Sanofi will post 4.28 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.